1. 1) Bénard-Laribière A, Miremont-Salame G, Perault-Pochat M, Noize P, Haramburu F. Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study. Fundam. Clin. Pharmacol., 29, 106–111 (2015).
2. 2) Lavan AH, O’Mahony D, Buckley M, O’Mahony D, Gallagher P. Adverse drug reactions in an oncological population: prevalence, predictability, and preventability. Oncologist, 24, e968–e977 (2019).
3. 3) Li X, Li H, Deng J, Zhu F, Liu Y, Chen W, Yue Z, Ren X, Xia J. Active pharmacovigilance in China: recent development and future perspectives. Eur. J. Clin. Pharmacol., 74, 863–871 (2018).
4. 4) Zhao Y, Wang T, Li G, Sun S. Pharmacovigilance in China: development and challenges. Int. J. Clin. Pharmacol., 40, 823–831 (2018).
5. 5) National Medical Products Administration. “The Annual Report on National Adverse Drug Reaction Monitoring in 2017 (2018).”: ‹http://www.cdr-adr.org.cn/xwdt/201804/t20180418_20010.html›, accessed 19 April, 2018.